Skip to content

Prophylactic Acetaminophen for Prevention Intraventricular Hemorrhage in Premature Infants

Prophylactic Acetaminophen for Prevention Intraventricular Hemorrhage in Premature Infants

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03024814
Enrollment
300
Registered
2017-01-19
Start date
2016-10-31
Completion date
2018-10-31
Last updated
2017-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraventricular Haemorrhage Neonatal

Brief summary

The purpose of this study is to determine whether acetaminophen is effective in prevention or reducing the severity of IVH in premature infants.

Detailed description

It will be a double-blind randomized control trial, single center. The study will include neonates with a gestational age of less than or equal 32 weeks and a birth weight of less than or equal 1500 g, and will randomly assigned to two treatment groups (see below). Infants will be randomized to equal-sized groups using block randomization with blocks of four. Stratified randomization for gender and gestational age will be included in the randomized blocks. Gestational age will be divided into two categories: 23 weeks +0 day to 27 weeks +6 days, and from 28 weeks +0 day to 32 weeks +6 days. Gender (2) × gestational age (2) will give 6 strata, requiring 6 separate random number lists to achieve randomization.

Interventions

DRUGAcetaminophen

The first group will receive acetaminophen as the following 1. Loading dose: 20 mg/kg in the first 12-24 hours To be diluted in D5W up to 3-5 ml and to be infused over 15 minutes. 2. Maintenance dose: 7.5 mg/kg after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days.

The second group will receive placebo (D5W) as the following 1. Loading dose: 3-5 ml in the first 12-24 hours To be infused over 15 minutes. 2. Maintenance dose: 3-5 ml after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days.

Sponsors

King Saud Medical City
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Hours to 6 Months
Healthy volunteers
No

Inclusion criteria

* Premature baby less than or equal 32 week and birth weight less than or equal 1500 g

Exclusion criteria

* Out-born babies, infants with major congenital anomalies, babies have IVH III, IV, High expectancy of early death

Design outcomes

Primary

MeasureTime frame
The incidence of intraventricular hemorrhage (IVH will be graded by Papile score) among the infants on acetaminophen compared to the infants on placebo.within the first week of age

Secondary

MeasureTime frame
The incidence of neonatal sepsis in the premature babies who received acetaminophenCorrected 40 weeks of gestational age or time of discharge will be used
The incidence of Necrotizing Enterocolitis (NEC) in the premature babies who received acetaminophenCorrected 40 weeks of gestational age or time of discharge will be used
The incidence of bronchopulmonary dysplasia (BPD) in the premature babies who received acetaminophenCorrected 40 weeks of gestational age or time of discharge will be used

Countries

Saudi Arabia

Contacts

Primary ContactMountasser Al-Mouqdafd, MD
m.almouqdad@ksmc.med.sa00966539095090

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026